Annual report pursuant to Section 13 and 15(d)

Segment reporting (Details) - Schedule of segment reporting information, by segment

v2.4.0.8
Segment reporting (Details) - Schedule of segment reporting information, by segment (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Jul. 31, 2014
Jul. 31, 2013
Jul. 31, 2012
Revenues:      
Clinical laboratory services $ 58,689 $ 55,889 $ 59,403
Product revenues 32,850 32,526 37,722
Royalty and license fee income 4,408 5,292 5,958
Total revenues 95,947 93,707 103,083
Operating expenses:      
Cost of clinical laboratory services 38,948 38,251 36,305
Cost of product revenues 15,320 16,584 19,668
Research and development 3,141 3,889 6,293
Selling, general and administrative 41,801 43,654 47,928
Provision for uncollectible accounts receivable 3,063 4,496 5,104
Legal fee expense 6,954 5,813 3,724
Impairment charges     24,540
Legal settlements, net (3,100)    
Operating (loss) income (10,180) (18,980) (40,479)
Other income (expense)      
Other 194 5 77
Foreign exchange gain 289 80 (540)
Cost of Clinical Laboratory Services [Member] | Clinical Labs [Member]
      
Share-based compensation included in above:      
Share-based compensation 8 9 10
Cost of Clinical Laboratory Services [Member] | Life Sciences [Member]
      
Share-based compensation included in above:      
Share-based compensation 1 1  
Cost of Clinical Laboratory Services [Member] | Consolidated [Member]
      
Share-based compensation included in above:      
Share-based compensation 9 10 10
Research and Development Expense [Member] | Life Sciences [Member]
      
Share-based compensation included in above:      
Share-based compensation 1 2 4
Research and Development Expense [Member] | Consolidated [Member]
      
Share-based compensation included in above:      
Share-based compensation 1 2 4
Selling, General and Administrative Expenses [Member] | Clinical Labs [Member]
      
Share-based compensation included in above:      
Share-based compensation 36 36 49
Selling, General and Administrative Expenses [Member] | Life Sciences [Member]
      
Share-based compensation included in above:      
Share-based compensation 6 10 59
Selling, General and Administrative Expenses [Member] | Other Segments [Member]
      
Share-based compensation included in above:      
Share-based compensation 542 487 597
Selling, General and Administrative Expenses [Member] | Consolidated [Member]
      
Share-based compensation included in above:      
Share-based compensation 584 533 705
Total [Member] | Clinical Labs [Member]
      
Share-based compensation included in above:      
Share-based compensation 44 45 59
Total [Member] | Life Sciences [Member]
      
Share-based compensation included in above:      
Share-based compensation 8 13 63
Total [Member] | Other Segments [Member]
      
Share-based compensation included in above:      
Share-based compensation 542 487 597
Total [Member] | Consolidated [Member]
      
Share-based compensation included in above:      
Share-based compensation 594 545 719
Clinical Labs [Member]
      
Revenues:      
Clinical laboratory services 58,689 55,889 59,403
Total revenues 58,689 55,889 59,403
Operating expenses:      
Cost of clinical laboratory services 38,948 38,251 36,305
Research and development 14 294 299
Selling, general and administrative 20,460 19,942 20,856
Provision for uncollectible accounts receivable 3,115 4,232 4,987
Legal fee expense 736 316 262
Legal settlements, net 2,000    
Total operating expenses 65,273 63,035 62,709
Operating (loss) income (6,584) (7,146) (3,306)
Other income (expense)      
Interest (43) (46) (5)
Other 56 49 28
(Loss) income before income taxes (6,571) (7,143) (3,283)
Depreciation and amortization included above 1,415 1,377 1,092
Share-based compensation included in above:      
Capital expenditures 643 757 921
Life Sciences [Member]
      
Revenues:      
Product revenues 32,850 32,526 37,722
Royalty and license fee income 4,408 5,292 5,958
Total revenues 37,258 37,818 43,680
Operating expenses:      
Cost of product revenues 15,320 16,584 19,668
Research and development 2,350 2,356 4,308
Selling, general and administrative 13,374 15,511 18,305
Provision for uncollectible accounts receivable (52) 264 117
Legal fee expense 940 57 536
Impairment charges     24,540
Legal settlements, net (5,100)    
Total operating expenses 26,832 34,772 67,474
Operating (loss) income 10,426 3,046 (23,794)
Other income (expense)      
Interest 9 13 23
Other 95 (71) 27
Foreign exchange gain 289 80 (540)
(Loss) income before income taxes 10,819 3,066 (24,284)
Depreciation and amortization included above 2,455 3,102 3,217
Share-based compensation included in above:      
Capital expenditures 195 231 443
Therapeutics [Member]
      
Operating expenses:      
Research and development 777 1,239 1,686
Total operating expenses 777 1,239 1,686
Operating (loss) income (777) (1,239) (1,686)
Other income (expense)      
(Loss) income before income taxes (777) (1,239) (1,686)
Depreciation and amortization included above 7 22 43
Other Segments [Member]
      
Operating expenses:      
Selling, general and administrative 7,967 8,201 8,767
Legal fee expense 5,278 5,440 2,926
Total operating expenses 13,245 13,641 11,693
Operating (loss) income (13,245) (13,641) (11,693)
Other income (expense)      
Interest (174) (21) 3
Other 43 27 22
(Loss) income before income taxes (13,376) (13,635) (11,668)
Depreciation and amortization included above 94 104 125
Consolidated [Member]
      
Revenues:      
Clinical laboratory services 58,689 55,889 59,403
Product revenues 32,850 32,526 37,722
Royalty and license fee income 4,408 5,292 5,958
Total revenues 95,947 93,707 103,083
Operating expenses:      
Cost of clinical laboratory services 38,948 38,251 36,305
Cost of product revenues 15,320 16,584 19,668
Research and development 3,141 3,889 6,293
Selling, general and administrative 41,801 43,654 47,928
Provision for uncollectible accounts receivable 3,063 4,496 5,104
Legal fee expense 6,954 5,813 3,724
Impairment charges     24,540
Legal settlements, net (3,100)    
Total operating expenses 106,127 112,687 143,562
Operating (loss) income (10,180) (18,980) (40,479)
Other income (expense)      
Interest (208) (54) 21
Other 194 5 77
Foreign exchange gain 289 80 (540)
(Loss) income before income taxes (9,905) (18,949) (40,921)
Depreciation and amortization included above 3,971 4,605 4,477
Share-based compensation included in above:      
Capital expenditures $ 838 $ 988 $ 1,364